开放获取期刊
  • 家
  • 作者指南
    • 作者指南
    • 目标和范围
    • 同行评审流程
    • 出版道德与不当行为声明
  • 档案
  • 提交稿件
  • Language
    English Spanish Russian German French Japanese Portuguese Hindi Telugu Tamil
  • +44-330-822-4832

国际标准期刊号: 2044-9038 (Print) 2044-9046 (Electronic)

临床实践

抽象的

Medical marijuana in cancer: harmful or harm reduction?

Alexandra Thielmann1, Paul J Daeninck

 

Marijuana (Cannabis sativa) has been a topic of much attention over several
decades, initially as a herbal remedy for a variety of ills, then as a mild hallucinogen used by the
‘counter culture’ of the 1960s and more recently as a focus of increasing medical and scientific
research. It also has become a popular alternative medication, and controversy continues to
swirl around its indications, despite widespread anecdotal evidence. Cannabinoids, isolated
from the plant as well as synthetically derived, have become a rapidly increasing area of
research and clinical use in certain medical conditions, such as cancer and cancer treatment.
Taken together, it becomes difficult for medical professionals to know whether these compounds
can be used with caution or should be rejected outright due to the potential harms, which
include the possibility of psychosis and driver impairment. Here, we explore the evidence for
cannabis and cannabinoid use in supportive cancer therapy, as well as sift through some of
the issues to be considered (including an explanation of the Canadian experience) as ‘medical
marijuana’ becomes more widely available.


 

:
  • 家
  • 关于我们
  • 期刊
  • 作者指南
  • 联系我们

开放获取期刊 © 2025

Get the App